Alabama Board of Medical Examiners Official Notice (May 26): Physicians, PAs, CRNPs, and CNMs Prohibited From Prescribing Non-FDA-Approved Research-Grade Peptides
The Alabama Board of Medical Examiners and Medical Licensure Commission issued a formal notice on May 26, 2026 prohibiting physicians, physician assistants, certified registered nurse practitioners, and certified nurse midwives from prescribing, administering, dispensing, recommending, or supplying any non-FDA-approved research-grade peptide to a patient. The notice explicitly declares patient consent forms acknowledging research-grade status ineffective and unable to mitigate professional or legal liability. Chairman Rogers cited the lack of FDA review as the basis: substances that have not gone through FDA review cannot be reliably verified for identity, manufacturing process, or risk profile. The state-level prohibition arrived alongside the FDA's April 23 removal of 12 peptides from Category 2 ahead of the July 23-24 PCAC meeting, illustrating that state-board enforcement is now layering on top of federal regulatory action.